Futibatinib Patent Expiration
Futibatinib is used for treating intrahepatic cholangiocarcinoma. It was first introduced by Taiho Oncology Inc
Futibatinib Patents
Given below is the list of patents protecting Futibatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lytgobi | US10434103 | Crystal of 3,5-disubstituted benzene alkynyl compound | Mar 31, 2036 | Taiho Oncology |
| Lytgobi | US11833151 | Pharmaceutical composition including sodium alkyl sulfate | Nov 05, 2039 | Taiho Oncology |
| Lytgobi | US9108973 | 3,5-disubstituted alkynylbenzene compound and salt thereof | Feb 23, 2033 | Taiho Oncology |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳